arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Stereotaxis, Inc.

STXS
$1.32 ▼ -0.06 (-4.69%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

Stereotaxis, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $132.0M
Dividend Yield
Revenue Growth -12.8%
Op. Margin -59.6%
ROIC -29.5%
FCF / Share $-0.04
Trailing P/E
Price / Book 10.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.67M
↓ -12.8%
Net Income Profit after all expenses
$-4.47M
↓ -16.8%
Operating Margin Operating profit as % of sales
-59.6%
↑ +37.4% 4th
FCF / Share Free cash flow per share
$-0.04
↓ -5.6%
Long-Term Debt Long-term obligations
$243.62K
↓ -75.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
4
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters